Healthcare

BLS Pharmaceuticals (ASX:BLS) describes manufacturing and distribution services as well as prescription and consumer health products under brands including Dr Watson. These are distinct commercial channels, each with its own procurement, inventory and customer requirements. Product diversity does not establish any particular level of …

In its July 2026 trading update, Cryosite (ASX:CTE) reported unaudited revenue of $16.7m for the financial year ended 30 June 2026, an increase of 18%. EBITDA rose 27% to $4.3m, while net profit after tax (NPAT) increased 20% to $2.3m. These were preliminary figures …

Cogstate (ASX:CGS) reported sales contracts executed of US$25.44 million in the March 2026 quarter. Across the nine months ended 31 March 2026, executed sales contracts totalled US$67.14 million. These amounts measure contracts signed, rather than revenue already recognised. The distinction matters because clinical trial …

Cogstate Ltd (ASX:CGS) operates in a market where the primary commercial and technological driver accelerating Cogstate's global enterprise value is the historic breakthrough in disease-modifying therapies for Alzheimer's disease.

Cryosite Limited (ASX:CTE) operates in a market where the fundamental commercial foundation supporting Cryosite's enterprise growth is the rapid expansion of global clinical drug development and precision medicine trials across Australia.

Careteq Ltd. (ASX:CTQ) operates in a market where the fundamental commercial catalyst driving Careteq's technology adoption is the severe structural demographic crisis facing healthcare systems globally.

The ARC Linkage Projects scheme is described as highly competitive and supports collaborations between Australian researchers and industry partners. The three-year project is titled A structural investigation into Lymphocyte activation gene-3 and will be led at Monash University's Biomedicine Discovery Institute. Immutep will provide …